New addition expands WCG's eClinical offerings for improving clinical trial start-up and management
WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that ePharmaSolutions (ePS) has joined its group of companies. Based near Philadelphia, PA, ePS is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials. Its proprietary solutions, including a cloud-based enterprise Clinical Trial Portal (CTP) and Electronic Trial Master File (eTMF), are used by 350,000 clinical research professionals in 130 countries who benefit from the improved coordination of study start up, site management, and regulatory document control.
“We are delighted to welcome ePharmaSolutions into the WCG family of companies. WCG and ePharmaSolutions share a powerful vision of how to improve clinical research trials – a cornerstone in the mission of WCG,” said WCG Chairman and CEO Donald A. Deieso, Ph.D. “Using ePS’ leading technology-driven solutions to assure that the activities of trial sites are coordinated, well informed, and efficiently managed will result in significant benefits to pharmaceutical companies, contract research organizations (CROs), institutions, and subjects.”
“Joining WCG will fulfill our company’s enormous potential as a beneficial force in the conduct of clinical trials,” said ePS Founder and CEO Lance Converse. “We look forward to contributing our technology and clinical support services to the broader mission of WCG – industry transformation,” he added. September has been an important month for our company; in addition to the WCG transaction, we were pleased to have been chosen as the winner of the ‘Disruptive Innovator of the Year’ award during the fourth annual Dpharm: Disruptive Innovations to Advance Clinical Trials conference – a recognition by leading industry professionals of the value of our work. ”
Like the other companies within WCG, ePharmaSolutions will continue to operate independently at its current locations, and will retain both its leadership and brand. WCG will support ePharmaSolutions as it continues to expand its platform solution with access to capital, complementary clinical expertise, corporate support, and integration of its technologies within the WCG family of companies.
ePharmaSolutions joins Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, Aspire IRB, New England IRB, and IRBNet as a member of the WCG family of companies.
Financial details about the transaction were not disclosed.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.